The introduction of biosimilars has transformed the therapeutic landscape for HER2-positive breast cancer by providing cost-effective alternatives to originator biologics without compromising efficacy, safety, or quality. Herzuma® (trastuzumab-pkrb), a biosimilar to trastuzumab, has demonstrated clinical equivalence in pivotal trials across early-stage and metastatic HER2-positive breast cancer. Regulatory approvals, supported by robust analytical, preclinical, and clinical comparability data, have enabled its integration into treatment guidelines in many countries, including Taiwan.

This presentation will review the scientific evidence supporting Herzuma's biosimilarity to the reference trastuzumab, including phase III trial data, real-world outcomes, and safety profiles. We will also discuss strategies to optimize patient access to HER2-targeted therapy through the adoption of biosimilars, focusing on health economic benefits, national reimbursement frameworks, and hospital formulary inclusion processes.

Furthermore, practical considerations for implementing Herzuma in clinical practice will be addressed, such as interchangeability, physician and patient education, and multidisciplinary collaboration. By leveraging biosimilars like Herzuma, healthcare systems can expand treatment availability, reduce financial barriers, and sustain high-quality cancer care in the era of increasing oncology drug expenditures.

The goal is to provide oncologists and healthcare decision-makers with evidence-based insights and actionable approaches for maximizing the clinical and economic value of HER2 biosimilars, ultimately improving outcomes for patients with HER2-positive breast cancer.